F-10: Cresco Labs Files Shelf Prospectus, Refinances Debt

Cresco Labs Inc. has filed a base shelf prospectus for up to $712.6 million in various securities and announced a US$325 million debt refinancing.

Summary

• Cresco Labs Inc. has filed a short form base shelf prospectus to offer and issue various securities, including subordinate voting shares, debt securities, subscription receipts, warrants, and units, over a 25-month period.
• The aggregate initial offering price for these newly registered securities is not to exceed $712,606,140.
• The company recently closed a refinancing of its senior secured credit facility on August 13, 2025, securing a new US$325 million term loan.
• The new term loan bears an interest rate of 12.5% per annum and matures on August 13, 2030.
• This new facility replaces a prior US$360 million facility, reducing total debt and extending maturity.
• The refinancing provides enhanced flexibility to prepay up to US$125 million at a reduced premium and contains no equity or convertible features.
• As of September 30, 2025, Cresco Labs had 340,337,989 Subordinate Voting Shares outstanding, representing approximately 25% of total voting rights.
• Super Voting Shares, held by founders, represent approximately 74% of voting rights, with a plan to repurchase them for $800,001 upon U.S. national exchange listing of Subordinate Voting Shares.
• The company operates as a vertically-integrated multi-state cannabis operator in eight U.S. states: California, Florida, Illinois, Massachusetts, Michigan, New York, Pennsylvania, and Ohio.
• The closing price per Subordinate Voting Share on the CSE was $1.82 on September 30, 2025.

Sentiment

Score: 7

Explanation: The filing indicates proactive financial management through debt refinancing and strategic positioning for future growth via a shelf prospectus. The debt reduction and maturity extension are positive. However, significant regulatory risks in the U.S. cannabis industry temper overall sentiment, as federal illegality remains a major overhang.

Positives

• Successfully refinanced senior secured credit facility, reducing total debt from US$360 million to US$325 million.
• Extended the maturity date of the senior secured term loan to August 13, 2030, providing longer-term financial stability.
• The new credit facility offers enhanced flexibility to prepay up to US$125 million at a reduced premium.
• The new facility contains no equity or convertible features, avoiding potential dilution from this specific debt instrument.
• The shelf prospectus provides future capital raising flexibility for various types of securities over a 25-month period.

Negatives

• The cannabis industry remains illegal under U.S. federal law, creating significant regulatory uncertainty and risk for operations.
• U.S. federal prosecutors have discretion to pursue cannabis-related violations, potentially leading to asset seizure or criminal charges for employees, directors, officers, managers, and investors.
• Non-U.S. citizens involved in cannabis businesses face the risk of being barred from entry into the United States for life.
• The Rohrabacher-Farr/Joyce Amendment only protects state medical cannabis laws, not adult-use businesses, leaving a significant portion of operations vulnerable to federal enforcement.
• The dual-class share structure, with Super Voting Shares holding approximately 74% of voting rights, concentrates control among founders, potentially limiting influence for Subordinate Voting Shareholders.

Risks

• The cultivation, sale, and use of cannabis is illegal under U.S. federal law pursuant to the Controlled Substance Act (CSA), classifying cannabis as a Schedule I drug.
• State laws legalizing cannabis for medical or adult-use purposes are in direct conflict with the CSA, and there is no guarantee these state laws will not be repealed or overturned.
• U.S. federal prosecutors have discretion to prosecute cannabis-related violations, which could lead to seizure of assets and arrest of employees, directors, officers, managers, and investors.
• Non-U.S. citizens involved in the cannabis business face the risk of being barred from entry into the United States for life.
• The Rohrabacher-Farr/Joyce Amendment, which prevents federal interference with state medical cannabis laws, must be renewed each fiscal year and does not protect adult-use businesses.
• Uncertainty regarding the U.S. Attorney General's policy on federal enforcement of cannabis laws poses a significant risk.
• The company's investments in the U.S. cannabis market may subject it to heightened scrutiny by regulators, stock exchanges, clearing agencies, and other U.S. and Canadian authorities.
• Investing in the company's securities is speculative and involves a high degree of risk, with potential for total loss of investment.

Future Outlook

The company aims to capitalize on opportunities presented by the changing regulatory environment in the U.S. cannabis industry. It anticipates potential future legalization of adult-use and/or medical cannabis under U.S. federal law and expects market size and growth in the states where it operates. The company plans for future business strategy, competitive strengths, goals, expansion, and growth, including new revenue streams, completion of contemplated acquisitions, application for and grant of additional licenses, expansion of existing cultivation and production facilities, and expansion into additional states and international markets.

Management Comments

• The Corporation's objective is to capitalize on the opportunities presented as a result of the changing regulatory environment governing the cannabis industry in the United States.

Industry Context

The U.S. cannabis industry operates in a complex and contradictory legal environment, with state-level legalization clashing directly with federal prohibition under the Controlled Substance Act. This filing highlights the ongoing tension, noting that while many states have legalized cannabis, federal enforcement remains a significant risk. The company's strategy to expand its multi-state operations and brands like Sunnyside* positions it to benefit from continued state-level market growth, but it remains highly vulnerable to any shift in federal policy. The refinancing of its debt at a 12.5% interest rate reflects the higher cost of capital typically faced by cannabis companies due to federal illegality, which limits access to traditional banking and financing. The dual-class share structure is also common in growth-oriented companies where founders seek to maintain control during expansion.

Comparison to Industry Standards

• The 12.5% interest rate on the new senior secured term loan is indicative of the higher cost of capital typically faced by U.S. cannabis operators due to federal illegality, which restricts access to conventional financing and often leads to higher borrowing costs compared to companies in federally legal industries.
• The dual-class share structure, with Super Voting Shares controlling approximately 74% of voting rights, is a common mechanism used by founders in high-growth or founder-led industries (e.g., tech, biotech) to maintain control and strategic direction, but it deviates from the one-share, one-vote standard preferred by many institutional investors for corporate governance.

Management Changes

Corporate Governance

Legal Proceedings

• The company faces a significant risk of U.S. federal authorities enforcing current U.S. federal law against its cannabis operations, which are illegal under the Controlled Substance Act, despite being legal under various state laws. This could lead to asset seizure, criminal charges for personnel, and being barred from entry into the U.S. for non-citizen employees/directors/investors.

Related Party Transactions

• All of the issued and outstanding Super Voting Shares are held by the Corporation's founders or their successors, heirs or permitted assigns (Charles Bachtell, Robert Sampson, Thomas Manning, and Brian McCormack Trust). These shares represent approximately 74% of the voting rights.

Stakeholder Impact

• **Shareholders:** Potential for dilution from future offerings under the shelf prospectus. The planned repurchase of Super Voting Shares could eventually simplify the voting structure and potentially increase the influence of Subordinate Voting Shareholders. However, the current dual-class structure concentrates control with founders.
• **Employees, Directors, Officers, Managers, and Investors:** Face significant personal risk, including potential arrest and criminal charges under U.S. federal law due to the cannabis industry's federal illegality. Non-U.S. citizens in these roles risk being barred from entry into the United States for life.
• **Creditors:** The recent debt refinancing reduced total debt and extended maturity, which is generally positive for creditors by improving the company's liquidity profile and reducing near-term repayment pressures. The 12.5% interest rate reflects the perceived risk of lending to a cannabis company.
• **Customers:** Continued operations and potential expansion, supported by capital raises, could lead to broader product availability and enhanced retail experiences through brands like Sunnyside*.

Next Steps

• The company may offer and issue various securities from time to time during the 25-month period that the shelf prospectus remains valid.
• Specific terms of any offering will be set forth in applicable prospectus supplements.
• The company will continue to evaluate, monitor, and reassess disclosure related to U.S. cannabis activities and risks, supplementing and amending public filings as needed.
• The company will repurchase all Super Voting Shares for $800,001 not later than the first business day after the first annual meeting of shareholders following any future listing of Subordinate Voting Shares on a U.S. national securities exchange.
• Upon no Super Voting Shares outstanding, the company may remove them from its authorized share structure without further shareholder approval.

Key Dates

Recommendation

The filing presents a mixed bag for investors. The debt refinancing is a positive step, reducing overall debt and extending maturity, which improves the company's financial flexibility. The shelf prospectus provides a mechanism for future capital raises, essential for growth in a capital-intensive industry. However, the overarching and significant risk remains the federal illegality of cannabis in the U.S. This fundamental conflict exposes the company and its stakeholders to substantial legal and operational uncertainties, including potential asset seizures and criminal charges. While the company is a leading multi-state operator, the regulatory environment creates an unpredictable investment landscape. The current share price of $1.82 reflects some of these risks. Until there is clearer federal guidance or reform, the stock is a 'hold' for investors who are comfortable with high risk and believe in the long-term potential of U.S. cannabis legalization, but it is not a 'buy' due to the significant regulatory overhang and potential for adverse federal action.

Keywords

Cresco Labs, Cannabis, SEC Filing, F-10, Shelf Prospectus, Debt Refinancing, Subordinate Voting Shares, Debt Securities, Subscription Receipts, Warrants, Units, Multi-State Operator, U.S. Cannabis Market, Regulatory Risk, Controlled Substance Act, Corporate Governance, Capital Raise